NEW YORK – Avistone Biotechnology said on Friday that it will begin studying its c-MET inhibitor ANS01 in a Canada-based Phase I trial enrolling patients with MET-altered solid tumors.
The Beijing-based firm has been studying the agent in Phase I clinical trials in both the US and China.
Both trials are designed to evaluate the safety, tolerability, and maximum tolerated dose of ANS01 in patients with locally advanced or metastatic solid tumors harboring pathogenic MET alterations, including MET mutations, amplifications, overexpressions, or fusions.
In April, China's National Medical Products Administration approved Avistone's c-MET inhibitor vebreltinib for patients with IDH-mutant astrocytoma or low-grade glioblastoma harboring a PTPRZ1-MET fusion.
The NMPA also approved the treatment — which Avistone is jointly developing with Apollomics — for patients with metastatic, MET exon 14 skipping non-small cell lung cancer.